Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group.
Cardiovascular complications
Cardiovascular phenotype
Extra-pancreatic effects
Glimepiride
Glucocrinology
Modern sulfonylureas
Myocardial ischemic preconditioning
Type 2 diabetes mellitus
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
23
02
2019
pubmed:
4
7
2019
medline:
4
7
2019
entrez:
4
7
2019
Statut:
ppublish
Résumé
The primary objective of this document is to develop practice-based expert group opinion on certain important but less discussed endocrine and metabolic effects of modern sulfonylureas (SUs) and their usage in the management of diabetes mellitus (DM). Modern SUs may be considered a panacea in DM care with their beneficial extra-pancreatic, pleiotropic, and cardiovascular effects. Safe glycemic control with SUs could be achieved with appropriate patient selection, drug and dosage selection, and patient empowerment. Additionally, sulfonylureas also exhibit certain endocrine and metabolic effects, which could be considered beneficial in the management of DM. In this regard, a group of international clinical experts discussed the less known beneficial aspects of SUs and safe and smart prescription of modern SUs in DM care. The concept of glucocrinology or the relationship of glycemia with the endocrine system was emphasized during the meetings. Clinical experts arrived at a consensus for the usage of modern SUs in the presence of other endocrine dysfunction and the impact of these drugs on endocrine health. The beneficial pleiotropic and cardiovascular effects of modern SUs were also discussed. The key discussion points were considered to develop clinical expert opinions for the use of modern SUs in persons with DM. Clinical expert opinions were developed for indications, pleiotropic benefits, cardiovascular outcomes, adherence, and safe use of modern SUs. Appropriate clinical judgement coupled with a patient-centered approach is crucial to achieve the best outcome in persons with DM. Owing to their safety, efficacy, extra-pancreatic benefits including effects on endocrine and metabolic aspects, and low cost of therapy, modern SUs could be considered as drugs/agents of choice for the treatment of diabetes. Sanofi India.
Sections du résumé
AIM
OBJECTIVE
The primary objective of this document is to develop practice-based expert group opinion on certain important but less discussed endocrine and metabolic effects of modern sulfonylureas (SUs) and their usage in the management of diabetes mellitus (DM).
BACKGROUND
BACKGROUND
Modern SUs may be considered a panacea in DM care with their beneficial extra-pancreatic, pleiotropic, and cardiovascular effects. Safe glycemic control with SUs could be achieved with appropriate patient selection, drug and dosage selection, and patient empowerment. Additionally, sulfonylureas also exhibit certain endocrine and metabolic effects, which could be considered beneficial in the management of DM. In this regard, a group of international clinical experts discussed the less known beneficial aspects of SUs and safe and smart prescription of modern SUs in DM care.
RESULTS
RESULTS
The concept of glucocrinology or the relationship of glycemia with the endocrine system was emphasized during the meetings. Clinical experts arrived at a consensus for the usage of modern SUs in the presence of other endocrine dysfunction and the impact of these drugs on endocrine health. The beneficial pleiotropic and cardiovascular effects of modern SUs were also discussed. The key discussion points were considered to develop clinical expert opinions for the use of modern SUs in persons with DM. Clinical expert opinions were developed for indications, pleiotropic benefits, cardiovascular outcomes, adherence, and safe use of modern SUs.
CONCLUSIONS
CONCLUSIONS
Appropriate clinical judgement coupled with a patient-centered approach is crucial to achieve the best outcome in persons with DM. Owing to their safety, efficacy, extra-pancreatic benefits including effects on endocrine and metabolic aspects, and low cost of therapy, modern SUs could be considered as drugs/agents of choice for the treatment of diabetes.
FUNDING
BACKGROUND
Sanofi India.
Identifiants
pubmed: 31267358
doi: 10.1007/s13300-019-0651-1
pii: 10.1007/s13300-019-0651-1
pmc: PMC6778594
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1577-1593Subventions
Organisme : Sanofi India
ID : 00
Références
Diabetes Ther. 2017 Aug;8(4):863-873
pubmed: 28646411
Int J Mol Sci. 2018 Sep 21;19(10):
pubmed: 30248910
Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):132-157
pubmed: 29535952
Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96
pubmed: 26425465
Am Heart J. 2011 Oct;162(4):620-626.e1
pubmed: 21982652
Acta Diabetol. 1995 Dec;32(4):273-8
pubmed: 8750768
Cardiovasc Diabetol. 2014 Jun 19;13:102
pubmed: 24943000
Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123
pubmed: 30559236
N Engl J Med. 2015 Jul 16;373(3):232-42
pubmed: 26052984
Diabetes Care. 2007 Nov;30(11):2773-8
pubmed: 17666462
J Med Invest. 2006 Feb;53(1-2):87-94
pubmed: 16538000
Metabolism. 2009 Feb;58(2):143-8
pubmed: 19154945
Circulation. 2001 Jun 26;103(25):3111-6
pubmed: 11425777
Curr Pharm Des. 2009;15(27):3179-92
pubmed: 19754390
J Pak Med Assoc. 2016 Apr;66(4):480-2
pubmed: 27122283
Stroke. 2017 Feb;48(2):388-393
pubmed: 27999139
Diabetes Care. 2010 Jun;33(6):1224-9
pubmed: 20215447
Diabetes Care. 2009 Dec;32(12):2143-8
pubmed: 19729527
Circulation. 2017 Oct 24;136(17):1643-1658
pubmed: 29061576
Diabetes Res Clin Pract. 2017 Oct;132:169-170
pubmed: 28962686
Curr Neuropharmacol. 2015;13(3):389-94
pubmed: 26411966
Lancet Diabetes Endocrinol. 2015 Jan;3(1):43-51
pubmed: 25466239
Ann Intern Med. 2018 Sep 18;169(6):394-397
pubmed: 30178023
Card Fail Rev. 2017 Apr;3(1):52-55
pubmed: 28785476
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
Diabetes Res Clin Pract. 2005 Jun;68(3):250-7
pubmed: 15936468
PLoS One. 2014 Feb 12;9(2):e82880
pubmed: 24533045
Circulation. 2018 Jul 31;138(5):458-468
pubmed: 29526832
Vasc Health Risk Manag. 2012;8:463-72
pubmed: 23028231
J Clin Endocrinol Metab. 2003 Feb;88(2):531-7
pubmed: 12574175
Lancet. 1998 Sep 12;352(9131):854-65
pubmed: 9742977
Ochsner J. 2014 Winter;14(4):616-32
pubmed: 25598727
Int J Cardiol. 2013 Jun 20;166(2):404-12
pubmed: 22112681
PLoS Med. 2016 Apr 12;13(4):e1001992
pubmed: 27071029
J Clin Endocrinol Metab. 2010 Nov;95(11):4993-5002
pubmed: 20702526
JAMA. 2019 Jan 1;321(1):69-79
pubmed: 30418475
Diabetes Care. 2002 Jan;25(1):107-12
pubmed: 11772910
Value Health. 2008 Jan-Feb;11(1):44-7
pubmed: 18237359
N Engl J Med. 2013 Apr 25;368(17):1613-24
pubmed: 23614587
Med Care. 2009 Aug;47(8):826-34
pubmed: 19584762
Cardiovasc Diabetol. 2014 Aug 10;13:123
pubmed: 25106079
J Diabetes Complications. 2017 Jul;31(7):1215-1221
pubmed: 28284707
Diabetes Care. 2003 Jul;26(7):2215-6
pubmed: 12832345
J Pak Med Assoc. 2018 Jun;68(6):963-965
pubmed: 30323371
Adv Ther. 2014 Dec;31(12):1287-305
pubmed: 25504156
Diabetes Care. 2017 Nov;40(11):1469-1478
pubmed: 28801475
Metabolism. 2006 May;55(5 Suppl 1):S20-7
pubmed: 16631807
Arch Intern Med. 2006 Sep 25;166(17):1836-41
pubmed: 17000939
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916